



JPL/4

Attorney's Docket No.: 1770-300US-1 – VC/dm

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jean-Pierre Julien et al.

Serial No.: 10/788,478

Filed: March 1, 2004

For: A NEW THERAPY FOR STROKE

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97 and 1.98**

Assistant Commissioner for Patents
Alexandria, Virginia 22313-1450
U.S.A.

Sir:

Submitted herewith on form PTO/SB/08A/B is a listing of documents known to applicants in order to comply with applicant's duty of disclosure pursuant to 37 C.F.R. § 1.56. Copies of the listed documents are also being submitted herewith to comply with the provisions of 37 C.F.R. § 1.97 and 1.98, with copies of English translations of non-English language references or of the pertinent portions thereof, if such translations are readily available. If applicable, English copies of foreign search reports citing at least some of the documents herein listed on PTO/SB/08A/B are also enclosed.

The references included herewith have been cited in the specification of the instant application.

The submission of any document which is not a statutory bar is not intended as an admission that any or all documents constitute prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove as a competent reference any

06/01/2004 SDENB0B1 00000146 195113 10788478

01 FC:1806 180.00 DA

document which is determined to be a prima facie prior art reference against the claims of the present application.


Statement of relevancy

The listed document is being submitted either in compliance with 37 C.F.R. 197(b), within three (3) months of the filing date of a national application or of the date of entry of the national stage in an international application; or pursuant to 37 C.F.R. §1.97(e)(1), within three (3) months from the date of an office action or of a search report issued in a foreign counterpart application citing each of the documents contained in the present statement; or pursuant to 37 C.F.R. §1.97(e)(2), within three (3) months from the first knowledge of each submitted document by any individual designated in C.F.R. §1.56(c), when each such document was not cited in a communication from a foreign patent office in a counterpart foreign application.


In the case of submissions under 37 C.F.R. §1.97(e)(1) and (2), the undersigned Attorney/Agent of Record hereby certifies that the enclosed references are hereby submitted within three months (1) from the issuance of the foreign action or search report, or (2) from said first knowledge, respectively.

The Commissioner is hereby authorized to charge the amount of \$180.00 to our Deposit Account Number 19-5113 to cover payment of Submission of an Information Disclosure Statement as prescribed in 37 C.F.R. 1.17(p) and any additional fees that may be required, or credit any overpayment (file number 1770-300US-1).

May 27, 2004

Respectfully submitted,

Valerie Carrier
Registration No. 56,011

OGILVY RENAULT
1981 McGill College, Suite 1600
Montréal (Québec) H3A 2Y3
CANADA
Tel.: (514) 847-4253



PTO/SB/08A/B 08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|---|--------------------------|--------------------|
|  INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | <i>Complete if Known</i> | |
| | | Application Number | 10/788,478 |
| | | Filing Date | March 1, 2004 |
| | | First Named Inventor | Jean-Pierre Julien |
| | | Art Unit | |
| | | Examiner Name | |
| Sheet | 1 | of | 4 |
| | | Attorney Docket Number | |

U.S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is

place a check mark here if English language Translation is
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file
(and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2
hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the
individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to
the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR
COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

| | |
|----------------------|--------------------|
| Application Number | 10/788,478 |
| Filing Date | March 1, 2004 |
| First Named Inventor | Jean-Pierre Julien |
| Art Unit | |
| Examiner Name | |

Attorney Docket Number 1770-300US-1 VC/dm

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| | | BEAULIEU, J.M. et al., "Induction of Peripherin Expression in Subsets of Brain Neurons After Lesion Injury or Cerebral Ischemia", Brain.Res. (2002) 946, 153-161 | |
| | | BENSIMON, G. et al., "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis", N. Eng. J. Med. (1994) 330, 585-591 | |
| | | CANO-ABAD, M.F. et al., "Calcium Entry Through L-type Calcium Channels Causes Mitochondrial Disruption and Chromaffin Cell Death", J. Biol. Chem. (2001) 43, 39695-39704 | |
| | | CHEN, M. et al., "Minocycline Inhibits Caspase-1 and Caspase-3 Expression and Delays Mortality in a Transgenic Mouse Model of Huntington Disease", Nat. Med. (2000) 6, 797-801 | |
| | | ROGERS, D.C. et al., "Behavioral and Functional Analysis of Mouse Phenotype: SHIRPA, a Proposed Protocol for Comprehensive Phenotype Assessment", Mammalian Genome (1997) 8, 711-713 | |
| | | ROGERS, D.C. et al., "Use of SHIRPA and Discriminant Analysis to Characterise Marked Differences in the Behavioural Phenotype of Six Inbred Mouse Strains", Behav. Brain Res. (1999) 105, 207-217 | |
| | | DERESKI, M.O. et al., "The Heterogeneous Temporal Evolution of Focal Ischemia Neuronal Damage in the Rat", Acta Neuropathol. (1993) 85, 327-333 | |
| | | DIRNAGL, U. et al., "Pathobiology of Ischaemic Stroke: An Integrated View", Trends Neurosci. (1999) 22, 391-397 | |
| | | DU, Y. et al., "Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease", Proc. Natl. Acad. Sci. (2001) 98, 14669-14674 | |
| | | GOLUB, L.M. et al., "Tetracyclines Inhibit Connective Tissue Breakdown by Multiple Non-Antimicrobial Mechanisms", Adv. Dent. Res. (1998) 12, 12-26 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

| | |
|----------------------|--------------------|
| Application Number | 10/788,478 |
| Filing Date | March 1, 2004 |
| First Named Inventor | Jean-Pierre Julien |
| Art Unit | |
| Examiner Name | |

Attorney Docket Number 1770-300US-1 VC/dm

| | | |
|--|---|--|
| | GOULDEN, V. et al., "Safety of Long-Term High-Dose Minocycline in the Treatment of Acne", Br. J. Dermatol. (1996) 134, 693-695 | |
| | GURNEY, M.E. et al., "Benefit of Vitamin E, Riluzole, and Gabapentin in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis", Ann. Neurol. (1996) 39, 147-157 | |
| | HACKE, W. et al., "Thrombolysis in Acute Ischemic Stroke: Controlled Trials and Clinical Experience", Neurology (1999) 53, S3-14 | |
| | JULIEN, J.P., "Amyotrophic Lateral Sclerosis: Unfolding the Toxicity of the Misfolded", Cell (2001) 104, 581-591 | |
| | KORENKOV, A.I. et al., "Treatment with Nimodipine or Mannitol Reduces Programmed Cell Death and Infarct Size Following Focal Cerebral Ischemia", Neurosurg. Rev. (2000) 23, 145-150 | |
| | KRIZ J. et al., "Differential Effects of Dihydropyridine Calcium Channel Blockers in Kainic Acid-Induced Experimental Seizures in Rats", Epilepsy Res. (2003) 52, 215-225 | |
| | KRIZ, J. et al., "Efficient Three-Drug Cocktail for Disease Induced by Mutant Superoxide Dismutase", Ann. Neurol. (2003) 53, 429-436 | |
| | KRIZ, J. et al., "Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis", Neurobiol. Dis. (2002) 10, 268-278 | |
| | LO, E.H. et al., "Mechanisms, Challenges and Opportunities in Stroke", Nat. Rev. Neurosci. (2003) 4, 399-415 | |
| | MARTIN, D. et al., "The Neuroprotective Agent Riluzole Inhibits Release of Glutamate and Aspartate from Slices of Hippocampal Area CA1", Eur. J. Pharmacol. (1993) 250, 473-476 | |
| | SINGH. B. "The Mechanism of Action of Calcium Antagonists Relative to Their Clinical Applications", Br. J. Clin. Pharmacol. (1986) 21, 109-121 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|--------------------|
| Substitute for form 1449PTO | | | | <i>Complete if Known</i> | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Application Number | 10/788,478 |
| Sheet | 4 | of | 4 | Filing Date | March 1, 2004 |
| | | | | First Named Inventor | Jean-Pierre Julien |
| | | | | Art Unit | |
| | | | | Examiner Name | |
| | | | | Attorney Docket Number | 1770-300US-1 VC/dm |

| | | |
|--|---|--|
| | The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, "Tissue Plasminogen Activator For Acute Ischemic Stroke", New Eng. J. Med. (1995) 333, 1581-1587 | |
| | TIKKA, T. et al., "Minocycline, a Tetracycline Derivative, Is Neuroprotective Against Excitotoxicity by Inhalation Activation and Proliferation of Microglia", J. Neurosci. (2001) 21, 2580-2588 | |
| | VAN DEN BOSCH, L. et al., "Minocycline Delays Disease Onset and Mortality in a Transgenic Model of ALS", NeuroReport (2002) 13, 1067-1070 | |
| | YRJANHEIKKI, J. et al., "A tetracycline Derivative, Minocycline, Reduces Inflammation and Protects Against Focal Cerebral Ischemia with a Wide Therapeutic Window", Proc. Natl. Acad. Sci. (1999) 96, 13496-13500 | |
| | YRJANHEIKKI, J. et al., "Tetracyclines Inhibit Microglial Activation and are Neuroprotective in Global Brain Ischemia", Proc. Natl. Acad. Sci. (1998) 95, 15769-15774 | |
| | ZHU, S. et al., "Minocycline Inhibits Cytochrome c Release and Delays Progression of Amyotrophic Lateral Sclerosis in Mice", Nature (2002) 417, 74-78 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.